bezafibrate has been researched along with Arterial Occlusive Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bisicchia, A; Di Salvo, MM; Ferlito, S; Gallina, M; Mugno, F | 1 |
| Flavell, DM; Hawe, E; Humphries, SE; Jamshidi, Y; MacCallum, PK; Meade, TW | 1 |
1 trial(s) available for bezafibrate and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein C-III; Apolipoproteins C; Arterial Occlusive Diseases; Base Sequence; Bezafibrate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Hypolipidemic Agents; Male; Middle Aged; Molecular Sequence Data; Peripheral Vascular Diseases; Polymerase Chain Reaction; Polymorphism, Genetic; Probability; Reference Values; Sensitivity and Specificity; Treatment Outcome | 2002 |
1 other study(ies) available for bezafibrate and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients after vasoactive and lipid-lowering treatment.
Topics: Arterial Occlusive Diseases; Bezafibrate; E-Selectin; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Vasoconstrictor Agents | 2000 |